ANXA4 and non-small cell lung carcinoma: It was found that TSN can enhance cisplatin sensitization against non-small cell lung cancer cells through targeting Anxa4 in NSCLC cells, decreasing the combination of Anxa4 with ATP7A, and decreasing the extracellular efflux of platinum.